@article{TLCR24459,
author = {Francesca Casaluce and Cesare Gridelli},
title = {Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {Suppl 4},
year = {2018},
keywords = {},
abstract = {Immunotherapies have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC), with worldwide pembrolizumab approval as upfront single agent for tumors with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of ≥50%, and recently with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approvals of pembrolizumab in combination with chemotherapy for non-squamous lung cancer, irrespective of PD-L1 status.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/24459}
}